

1.	Record Nr.	UNIORUON00435167
	Autore	Bank Leu AG (Zurigo)
	Titolo	Antike Münzen : kelten griechen römer byzantiner : Auktion 45, 26. Mai 1988, Zürich / Bank Leu AG Zürich - Zürich : Bank Leu AG, c1988 - 87 p., [42] c. di tav. : ill. ; 30 cm
	Disciplina	737.4093
	Soggetti	MONETE ANTICHE - Aste - Cataloghi
	Lingua di pubblicazione	Tedesco
	Formato	Materiale a stampa
	Livello bibliografico	Monografia
2.	Record Nr.	UNINA9910438010903321
	Titolo	Lymphoma : diagnosis and treatment / / Anas Younes, Bertrand Coiffier editors
	Pubbl/distr/stampa	New York, : Humana Press, 2013
	ISBN	1-62703-408-0
	Edizione	[1st ed. 2013.]
	Descrizione fisica	1 online resource (414 p.)
	Collana	Current clinical oncology ; ; v. 43
	Altri autori (Persone)	YounesAnas CoiffierBertrand
	Disciplina	616.99 616.99/446 616.99446
	Soggetti	Lymphomas - Diagnosis Lymphomas - Treatment
	Lingua di pubblicazione	Inglese
	Formato	Materiale a stampa
	Livello bibliografico	Monografia
	Note generali	Description based upon print version of record.
	Nota di bibliografia	Includes bibliographical references and index.
	Nota di contenuto	Preface; Contents; Contributors; 1: The World Health Organization Classification of Lymphoid Neoplasms; Introduction; Precursor Lymphoid Neoplasm; B-Lymphoblastic Leukemia /Lymphoma, NOS; T-Lymphoblastic Leukemia/Lymphoma; Mature B-Cell Neoplasms;

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL); B-Cell Prolymphocytic Leukemia; Splenic Marginal Zone Lymphoma; Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia; Plasma Cell Neoplasms; Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma); Nodal Marginal Zone B-Cell Lymphoma; Follicular Lymphoma; Primary Cutaneous Follicle Center Lymphoma; Mantle Cell Lymphoma; Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; T-Cell-/Histiocyte-Rich Large B-Cell Lymphoma; DLBCL with a Predominant Extranodal Location; Primary Mediastinal (Thymic) Large B-Cell Lymphoma; Intravascular Large B-Cell Lymphoma; Primary Cutaneous DLBCL, Leg Type; Large-Cell Lymphomas of Terminally Differentiated B Cells; ALK-Positive Large B-Cell Lymphoma; Plasmablastic Lymphoma; Primary Effusion Lymphoma; Burkitt Lymphoma; B-Cell Lymphoma, Unclassifiable, with Features Intermediate Between DLBCL and Burkitt Lymphoma; B-Cell Lymphoma, Unclassifiable, with Features Intermediate Between DLBCL and Classical Hodgkin Lymphoma; Mature NK-Cell/T-Cell Neoplasms; T-Cell Prolymphocytic Leukemia; Aggressive NK-Cell Leukemia; EBV+ T-Cell Lymphoproliferative Disorders of Childhood; Adult T-Cell Leukemia/Lymphoma (ATLL); Extranodal NK-/T-Cell Lymphoma, Nasal Type (ENK/TCL, NT); Enteropathy-Associated T-Cell Lymphoma (EATL); Hepatosplenic T-Cell Lymphoma (HSTL); Subcutaneous Panniculitis-Like T-Cell Lymphoma (SPTCL); Hodgkin's Lymphoma; Follicular Lymphoma (FL); Mantle Cell Lymphoma (MCL); Burkitt's Lymphoma (BL); High-Throughput Sequencing (HTS); Array-Based Comparative Genomic Hybridization (aCGH); Profiling of Noncoding RNA; Epigenetic Profiling; Proteomic Profiling; Metabolic Profiling; Conclusion; References; 3: Molecular Profiling of Peripheral T-Cell Lymphomas; Background; Gene Expression Profiling of Peripheral T-Cell Lymphoma; Histogenesis of PTCLs; Molecular Pathogenesis; Targeted Therapy; Tyrosine-Kinase Inhibitors; Histone Deacetylase Inhibitors; Antiangiogenic Therapy; Monoclonal Antibodies; Prognostication

Sommario/riassunto

Recently, understanding the molecular pathogenesis of malignant lymphomas has led to improvement in the diagnostic precision and to the identification of a variety of molecular therapeutic targets. In addition, new drugs have been approved in the US and Europe, resulting in changes in the standard of care of several types of lymphoid malignancies. Comprehensive in scope and developed by a team of internationally renowned authors, *Lymphoma: Diagnosis and Treatment* provides a timely update on the most important advances in the biology, diagnosis, and therapy of lymphomas. As part of the Current Clinical Oncology series, *Lymphoma: Diagnosis and Treatment* will be of value to medical oncologists, hematologists, radiation oncologists, and all physicians involved in the care of patients with lymphoid malignancies.